Selpercatinib Expands RET Fusion Testing Across Tumors
FDA’s traditional approval of selpercatinib expands tumor-agnostic treatment for RET fusion-positive solid tumors, covering eligible adults and children aged two years and older.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.